Will tucatinib/tucatinib be included in medical insurance in 2024?

Tucatinib/TucatinibThe original drug has not been approved by the National Medical Products Administration for marketing in China, so it will not be included in the medical insurance list as of 2024. The original drug Tucatinib is currently only approved for marketing in some overseas countries, such as the United States, the European Union, Canada and other places, and is sold under the trade name Tukysa. At the same time, generic drugs of tucatinib have also been launched overseas. Common manufacturers include Laos No. 2 Factory, Bangladesh Ziska Pharmaceuticals, Bangladesh Everest Pharmaceuticals, etc. The ingredients of the drugs are basically the same as those of the original drugs, and there may be differences in price and other aspects.

Tucatinib is a cancer drug used to treat locally advanced or metastatic breast cancer (that has spread to other parts of the body), as well as HER2-positive breast cancer. This means that cancer cells produce a protein, HER2, on their surface that stimulates cancer growth. Tucatinib is used with two other drugs, capecitabine and trastuzumab, and after at least 2 other treatments for HER2-positive cancer have been tried. The active ingredient in tucatinib is tucatinib. Tucatinib was subsequently approved for the treatment of unresectable or metastatic colorectal cancer and can also be used in combination with trastuzumab to increase its efficacy.

Tucatinib is currently only available by prescription, and treatment should be initiated and supervised by a physician experienced in cancer treatment. It is administered orally and the recommended dose is 300 mg twice daily. Patients may also receive capecitabine and trastuzumab on certain days of the 21-day cycle. As long as the cancer is not getting worse and side effects are tolerable, treatment can continue. If certain side effects occur, your doctor may recommend reducing your dose of tucatinib or stopping treatment temporarily or permanently.